Rituxan in Churg Strauss Syndrome With Renal Involvement

Status Terminated

Clinical Trial Summary

Churg-Strauss Syndrome (CSS) is a disease characterized by asthma, abnormally high amounts of eosinophils (a type of white blood cell), and blood vessel inflammation. About 25% of CSS patients develop kidney disease. The goal of this pilot study was to evaluate the safety and effectiveness of Rituximab in inducing remission of kidney disease in patients with CSS.

Clinical Trial Description

Churg-Strauss syndrome (CSS) is a small vessel systemic vasculitis associated with asthma and eosinophilia that causes glomerulonephritis in about 25% of patients. Rituximab is a chimeric anti-CD20 monoclonal antibody that depletes B cells and is effective in numerous autoimmune disease including antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The aim of this study was to evaluate the safety and efficacy of Rituximab in inducing remission of renal disease activity in patients with CSS. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00424749
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Terminated
Phase	Phase 2
Start date	June 2007
Completion date	July 2009

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01729624` - PRO Development for ANCA Associated Vasculitis	N/A
Completed	`NCT02190916` - Vasculitis Illness Perception (VIP) Study	N/A
Recruiting	`NCT02967068` - VCRC Tissue Repository
Completed	`NCT02190942` - VCRC Patient Contact Registry Patient-Reported Data Validation Study
Completed	`NCT00307593` - RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides	N/A
Completed	`NCT02190929` - Educational Needs of Patients With Systemic Vasculitis	N/A
Active, not recruiting	`NCT00006055` - Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases	N/A
Active, not recruiting	`NCT03557060` - NUCALA® Special Drug Use Investigation (EGPA, Long-term)
Completed	`NCT00307671` - Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years	Phase 4
Active, not recruiting	`NCT00399399` - CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors	Phase 4
Completed	`NCT02020889` - A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis	Phase 3
Completed	`NCT02176070` - Reproductive Health in Men and Women With Vasculitis	N/A
Completed	`NCT00266565` - Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome	Phase 1/Phase 2
Recruiting	`NCT06046222` - Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis	Phase 2
Recruiting	`NCT04316494` - Hydroxychloroquine in ANCA Vasculitis Evaluation	Phase 4
Active, not recruiting	`NCT04551989` - Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan
Recruiting	`NCT04671446` - Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
Completed	`NCT03036670` - Eosinophilic Granulomatosis With Polyangiitis Cohort
Terminated	`NCT02728271` - Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome	Early Phase 1
Recruiting	`NCT00315380` - Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis